Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Ekf Diagnostics Holdings Plc LSE:EKF London Ordinary Share GB0031509804 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.60 -0.76% 78.80 79.00 81.60 81.60 78.60 81.20 145,865 16:35:15
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Health Care Equipment & Services 44.9 5.5 0.8 97.3 359

Ekf Diagnostics Share Discussion Threads

Showing 2851 to 2871 of 3350 messages
Chat Pages: Latest  122  121  120  119  118  117  116  115  114  113  112  111  Older
DateSubjectAuthorDiscuss
18/12/2020
16:35
richman, not a tax expert but agree with your reading of demerger exemption with respect to RENX & EKF. I read these dividend in specie of shares representing taxable income. It will be in one of those boxes in the investment income section of the Tax Return should think. It will add a complication if for example VRCI shares that I received are treated as income this year & their proceeds is assessed after lock in period in a differently in different tax year. I am in the position of having so many share transactions this year that I expect to declare all of them as trading activity (& non chargeable to CGT). This will be the first year of trading in shares so I'll be on a learning curve. I'll take advice on this in case there is a possibility of splitting treatment this year between trading & CGT somehow not miss out on CGT nil rate band. My transactions in some shares are quite different from others - certainly holding for growth in some & frantically day trading in others. RENX has been a LTH for a gain but my dodging the bullet on AVCT is trading in my mind at least.
red171
18/12/2020
12:37
Self designated village "he knows what" on it. Rookie needs to be reminded he's on filter. Back to more important matters - the 2020 price for avg Joe in this share is about 60. That gives a "paper profit" of about +6% ytd. Such calculations exclude a few geniuses on here who got in at 16:):):)
tongosti
18/12/2020
12:07
This Tong guy really is a sandwich short of a picnic. Wan like many others has been holding EKF well before you even knew it existed. Hence the term long term investor. Get a grip on your delusion Tong
mg1982
18/12/2020
07:57
Covid-19 testing continues to expand rapidly in the UK and elsewhere, with what can only be described as a massive expansion in testing in early 2021 (antigen and PCR testing). Just two examples - Testing for COVID-19 before a hospital procedure Published 15 December 2020 Who can take the test The test is suitable for the following people: adults aged 18 and over: self-test (unless unable to do so) teenagers aged 12 to 17: self-test with adult supervision children 11 and under: adult to test (see instructions on how to test a child) hTTps://www.gov.uk/government/publications/testing-for-coronavirus-before-hospital/testing-for-covid-19-before-a-hospital-procedure Press release Staggered rollout of coronavirus testing for secondary schools and colleges Testing offered to schools and colleges to minimise cases and transmission of the virus with return of students after Christmas The government has today (17 December) confirmed that all secondary schools and colleges in England will be able to test more of their staff and students in a round of free coronavirus testing from the first week of January. Published 17 December 2020 Schools and colleges will be able to establish testing to offer students two rapid tests three days apart, with positive results confirmed by a lab-based PCR test. hTTps://www.gov.uk/government/news/staggered-rollout-of-coronavirus-testing-for-secondary-schools-and-colleges Clearly EKF were experiencing and indeed anticipating increased demand, as EKF's new pack and fill facilities with a few clean rooms in Cardiff has apparently been completed and handed over - 16th December EKF Diagnostics manufactures a key component in the Covid-19 testing regime – PrimeStore MTM, which is used to transport a nasal swab with a patient’s sample from the point of care to the laboratory. PrimeStore MTM inactivates the sample so it is no longer ‘live’ and preserves the RNA that will be tested in the lab to determine whether the patient has COVID-19. The company has its main manufacturing facility at Avon House, Penarth and urgently needed additional space nearby. Martyn Lewis of EKF Diagnostics, said: “We wanted somewhere that could easily be adapted for our purposes and have enough space to ensure staff safety during their working day. We settled on Unit 20 pretty quickly.” EKF has created more than 30 new jobs including production line operatives, and in customer services, purchasing, operations and logistics to cope with the demand for its product and expects to employ more staff in the short term as it settles into the new unit. Mileway, the leading pan-European last mile logistics real estate company, and landlord for Llandough Trading Estate, worked closely with EKF, offering them a lease agreement that best supports their Covid-19 work. hTTps://newsfromwales.co.uk/news/new-lettings-at-llandough-trading-estate-in-cardiff-knight-frank/
wan
17/12/2020
20:05
i am a longstanding holder of EKF, as a result of which i hold RENX, VRCI and shortly Trellusanyone got an informed view on the tax treatment of the dividends in specie?-my understanding was reorganisation via demerger so no tax charge on receipt of the new shares and EKF base cost apportioned for cgt purposes when shares soldhowever i did read that for the statutory demerger exemption to apply (and thus no tax charge on receipt of the new shares) the parent co must retain at least 75%-not the case with RENX (think 50%-60%) or Trellus (around 30%)
richman777114
17/12/2020
18:07
Schadenfreude is a nasty complaint ...... but fun while it lasts.
boadicea
17/12/2020
16:19
Just heard Tong got in at 60p via DM cos Mr Market had a word with him. Wait for his new blag. Never seen someone so indecisive and still lecture everyone on what the markets telling him
mg1982
17/12/2020
13:14
As indicated by the CEO, Trellus will not be the last value creation to come out of the EKF/Mount Sinai partnership. And although EKF will also be a cash dividend payer, the spinout opportunities (and ultimately the best use of EKF 'growing' cash pile) will return greater value to investors. Even like those of us who follow EKF closely, we only have the track record to go by, and in this regard Renalytix delivered circa 23p to patient EKF investors and then went onto deliver a lot more, including Verici (and I suspect there is more to come from both of these). I firmly believe Trellus will follow a similar path in terms of delivery to EKF investors. And I am sure most investors are fully behind the management with regard to this value creation policy. What we don't know is what's coming next in terms of potential spinouts, but only the patient investors will find out and ultimately realize the benefit. In the meantime, the core business continues to advance and grow, as do their relationships, which are now extending further.
wan
17/12/2020
11:52
Do I detect anxiety with wider markets breaking into fresh ath while ekf refusing to participate? LOLPS. You'd better pray we don't close below 58 because the floodgates will v likely open then!
tongosti
17/12/2020
10:48
A typically shrewd remark from Mr Market Toodle Pip
chris16041
17/12/2020
07:53
Two excellent and worthwhile reads for those who will 'effectively' be getting Trellus Health shares today - The first one particularly centres on pharma's interest and involvement (cue Roche?) - How pharma needs to change for the era of digital health December 16, 2020 Experts from Healthware Group explore how companies can rebuild their approach to digital from the ground up for the benefit of patients. Digital is not just a nice-to-have for pharma companies – it’s a necessity for ensuring that patients have the best possible outcomes in modern healthcare systems. With digital tools and techniques being able to improve almost every aspect of a pharma company’s business, from R&D to sales, there’s no excuse for not implementing digital transformation at every level – and that’s not even mentioning new opportunities for life science firms to produce digital products that can complement or even replace traditional medicines. Full article - hTTps://deep-dive.pharmaphorum.com/magazine/patients-and-partnerships-2020/how-pharma-needs-to-change-for-the-era-of-digital-health/ The second article has a pharma element too, but also notes that Covid-19 will also be a factor going into 2021 and how regulated digital health tools can also assist in public health emergencies - Dec 16, 2020 Four Trends For Regulated Digital Health In 2021 A push to virtual care has immediately benefitted telehealth and remote patient monitoring. As digital health is more encompassing, there is an added focus across the board on regulated digital health solutions, including digital therapeutics and software as a medical device. Several factors will influence digital health’s advancement. Here are a few trends we see impacting the industry in 2021. Full story - hTTps://www.forbes.com/sites/forbestechcouncil/2020/12/16/four-trends-for-regulated-digital-health-in-2021/?sh=653bfe743c1a
wan
16/12/2020
12:48
The best research is validated by Mr Market wan. Fundamentals (hazy as they are to most) are nothing unless the market agrees with them. Read Jesse Livermore on the topic. PS. Just covered my mistake on the long side for a little less than -5%. Guess +48% trading ekf will have to do for the moment.
tongosti
16/12/2020
12:29
It's early days for the telehealth market but this article gives an insight to its potential, particularly in the US. Consolidation will arrive at some point with lots of scope for M&A. Https://www.businesswire.com/news/home/20200805005586/en/Telehealth-Industry-Expected-to-Grow-from-26.4-Billion-in-2020-to-70.19-Billion-by-2026-at-a-CAGR-of-17.7---ResearchAndMarkets.com
jacks13
16/12/2020
11:53
A restrained post, for now! Does such a thing as a shakeout really exist? Who knows but I would suggest that hanging onto your EKF shares (or accumulating more) could ultimately prove to be very lucrative (and for more reasons than an IPO of Trellus alone). I already know from previous research that the IBD opportunity is very large and has attracted global player interest. I have just finished some in-depth research, which was revealing to say the least! But consequently I do now have some more research to do. What I will say at this juncture, is that Roche are particularly interested in transforming IBD care to improve outcomes and patients lives. This interest (which is extensive) starts to demonstrate the size of the global IBD market, but the other very interesting fact is that there is already a strong relationship and collaboration between Roche and Mount Sinai with regard to IBD, and not just from a pharmaceutical perspective! Perhaps more from me later in this regard. Please conduct your own research when making investment decisions, as the originator, or the threads contributors, could be either wrong or inaccurate.
wan
16/12/2020
11:50
But you did play macho tongosti. The time to buy was Monday. You'll learn, given time. Still a lot of growing up to do.
jacks13
16/12/2020
11:17
Tong, Seriously? I thought you were up 10% already? Your pal Mr Market ain't giving you the goods is he?
mg1982
16/12/2020
10:27
This bad boy not acting right. About -2% off of my entry price yesterday. Still in but if my stop level comes to play then cover the trade and wait for the next one is the mantra. Never play macho with Mr Market!
tongosti
16/12/2020
07:58
Just a quick note from attending the General Meeting. During discussions (from memory) reference was made to Trellus Health having a unique offering addressing a very large market in the US, with plans to expand into other markets, including (and possibly quite soon) the UK, followed by Europe. One of my questions was; "Beyond the initial focus on IBD, what other chronic conditions are you planning to address?". Initially (over the next 12-18 months I recall) they will be very focused on delivering and addressing Inflammatory Bowel Disease (IBD), which is a huge market. But Apparently the Trellus offering could quite easily be adapted to address Irritable bowel syndrome (IBS), which is not as big as the IBD market, but would be relatively easy to bolt on. Other than that, addressing other chronic diseases are most certainly on the radar (watch this space!).
wan
15/12/2020
13:19
BBC News - 'Huge expansion' of secondary school Covid tests in January HTTPS://www.bbc.co.uk/news/education-55318628
speedsgh
15/12/2020
13:04
Trellus will almost certainly follow the path of Verici DX and open well above the IPO price, I also expect there to be an open offer but let’s see on that - if there is then it’ll be very oversubscribed... Kudos to the EKF management for their excellent work in building such a fruitful partnership with Mount Sinai, long may it continue!
74tom
15/12/2020
12:54
Listen to what the market is telling you is the mantra. Gone LONG on back of most recent price action. Wish me luck ladies!
tongosti
Chat Pages: Latest  122  121  120  119  118  117  116  115  114  113  112  111  Older
ADVFN Advertorial
Your Recent History
LSE
EKF
Ekf Diagno..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210415 16:19:38